<?xml version='1.0' encoding='utf-8'?>
<document id="22375423"><sentence text="[Identification of metabolites of nobiletin in rats using ultra-performance liquid chromatography coupled with triple-quadrupole mass spectrometry]."><entity charOffset="34-43" id="DDI-PubMed.22375423.s1.e0" text="nobiletin" /></sentence><sentence text="In this study, metabolism of nobiletin in rats was studied using ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS)"><entity charOffset="29-38" id="DDI-PubMed.22375423.s2.e0" text="nobiletin" /></sentence><sentence text=" As a result, seven major metabolites were found in bile, urine and serum of rats" /><sentence text=" Three phase I products were assigned to be demethyl and di-demethyl products, and other four phase II products were assigned to be glucuronic and sulfonic conjugates"><entity charOffset="44-52" id="DDI-PubMed.22375423.s4.e0" text="demethyl" /><entity charOffset="57-68" id="DDI-PubMed.22375423.s4.e1" text="di-demethyl" /><pair ddi="false" e1="DDI-PubMed.22375423.s4.e0" e2="DDI-PubMed.22375423.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22375423.s4.e0" e2="DDI-PubMed.22375423.s4.e1" /></sentence><sentence text=" The four phase II metabolites were reported for the first time" /><sentence text=" Among the metabolites found in the present study, the glucuronic conjugates of demethyl-nobiletin played a predominant role in the metabolic pathway, indicating that its potential role for glucuronidation-related factors, such as gene polymorphism, drug-drug interaction, etc" /><sentence text=", in changing the active and toxic effect of nobiletin and that it should be paid more attention in further development"><entity charOffset="45-54" id="DDI-PubMed.22375423.s7.e0" text="nobiletin" /></sentence><sentence text="" /></document>